FibroGen Inc KOL Investor Event Series Part I (Virtual) Transcript
Good morning, and welcome to the FibroGen Virtual KOL Investor Event. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the FibroGen website following the conclusion of the event.
I'd now like to turn the call over to Thane Wettig, Chief Executive Officer of FibroGen. Please go ahead, Thane.
Thank you, Tara, and good morning, everybody. We're excited that you have been able to join us for our first virtual KOL investor event, where today, we're going to have the opportunity to review pamrevlumab clinical program in pancreatic cancer and it's near -- 2 near-term readouts in pancreatic cancer as well.
First, a quick mention of our disclosure statement. We will have information in this presentation which contains forward-looking statements that involve substantial risks and uncertainties. And so, please keep this in mind.
We have an important next few months at FibroGen, given our purpose to accelerate the development of novel
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |